Company Overview and News
Stop missing out on important events!
CAMPBELL, CA--(Marketwired - March 13, 2018) - VIVUS,Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter and year ended December 31, 2017 and provided a business update. (11-0)
Good day, everyone, and welcome to Neurocrine Biosciences’ Reports Fourth Quarter and Year End 2017 Results. [Operator Instructions] Please note, today's call is being recorded. [Operator Instructions] (16-0)
The following slide deck was published by Mitsubishi Tanabe Pharma Corp. ADR in conjunction with their 2017 Q3 earnings call. (2-0)
TEL AVIV (Reuters) - Israeli high-tech acquisitions and initial public offering activity soared to $23 billion in 2017 from $10 billion in 2016 due to the $15.3 billion purchase of Mobileye by Intel Corp (INTC.O), data published on Wednesday showed. (17-1)
Halvorsen's 13F portfolio value increased from $14.85B to $15.44B. The number of positions increased from 53 to 59. (1331-7)
This was written for our subscribers last week, and since then the stock is down 15% on EPS loss. (19-0)
CAMPBELL, CA--(Marketwired - November 07, 2017) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter ended September 30, 2017 and provided a business update. (11-0)
Good day, ladies and gentlemen, and welcome to the Qumu Third Quarter 2017 Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] (6-0)
NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has appointed Mr. Paris Panayiotopoulos to its Board of Directors. (152-0)
The following slide deck was published by Mitsubishi Tanabe Pharma Corp. ADR in conjunction with this event. (2-0)
- Akebia Provides Mitsubishi Tanabe with Option to Access Global Phase 3 Vadadustat Data for Payments of up to $25 Million - (19-0)
With growing awareness about animal health, companies are growing more conscious of treating animals in a socially acceptable manner. If you look at prominent makeup brands, a lot of these multi-million dollar companies make explicit claims about livestock health and responsible handling. Similarly, with research and surveys discovering more complex diseases, the health sector is working overtime to find cures for healthier livestock.
Eylea continues to witness solid demand in approved indications. Besides, the company is striving to further expand the drug’s label. (1-0)
JERSEY CITY, N.J., Aug. 8, 2017 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc., today announced RADICAVA (edaravone), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is now available for treatment in the United States. RADICAVA, the first FDA-approved ALS treatment option in more than 20 years, has been demonstrated to slow the decline in the loss of physical function in ALS patients by 33 percent in its clinical trial.
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 2018 Earnings Conference Call July 31, 2017 12:00 PM ET